Aegros Releases Top-Line Interim Clinical Trial Results of its COVID-19 Hyperimmune – TGA Application to follow
WATCH NOW – Aegros Founders and Chief Medical Officer discuss the interim CHAT results. Date: 01 December 2023 Aegros, an Australian clinical-stage biopharmaceutical company leader in the development and manufacture of plasma derived medicinal products (PDMPs), today announced positive top-line interim results from its CHAT clinical trial. Top-line interim results indicate that Aegros’ COVID-19 hyperimmune […]
